EGFR and neoplasm: In preclinical studies, the tumor uptake of [89Zr]Zr-DFO-nimotuzumab increased up to 168 h pi, but HER1 expression in breast and colorectal carcinoma models was clearly visualized as early as 24 h pi [123].